AGM Statement

RNS Number : 0264V

Alliance Pharma PLC

22 May 2008

 



For immediate release

22 May 2008

ALLIANCE PHARMA PLC

('Alliance Pharma' or 'the Company')

AGM Statement

Alliance Pharma plc (AIM: APH) the speciality pharmaceutical company, will hold its Annual General Meeting in London this morning.

Michael Gatenby, the Company's Chairman, will make the following comments:

'I am pleased to report that trading in the first four months of 2008 has been in line with expectations and it is encouraging to see that the improved performance in the second half of 2007 is continuing into 2008. In the UK our dermatology product Hydromol and in China our pregnancy nutritional support product Forceval have been particularly strong performers.

'We announced last week that application for registration of our development product Isprelor is now unlikely to occur before 2011.  Whilst it is disappointing that the project has been delayed, we are obviously keen to ensure that the application is sufficiently robust when it is submitted.

'The uncertainties of product development underline the importance that we placed at the middle of last year on improving our trading performance, resulting in trading in the first four months of 2008 being substantially ahead of the same period the previous year.'

For further information: 

Alliance Pharma plc	+ 44 (0) 1249 466966
John Dawson, Chief Executive
Richard Wright, Finance Director
www.alliancepharma.co.uk
Buchanan Communications	+ 44 (0) 20 7466 5000
Mark Court / Rebecca Skye Dietrich
Numis Securities	+ 44 (0) 20 7260 1000
David Poutney / Michael Meade

 

END

 

 

MSCFKDKNFBKDDPB